Network meta-analysis (NMA) is an accepted statistical method used to model the clinical- and cost-effectiveness of treatments in the absence of data from head-to-head randomised controlled trials (RCTs). In the fifth of our DRG investigative series, we assess submission guidelines by health technology assessment (HTA) bodies and suggest a reporting checklist for NMAs to support manufacturers in meeting the requirements for global technology appraisal.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now